InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
August 09, 2023 12:30 ET | Interpace Biosciences, Inc.
 ●Q2 Revenue of $11.0 million; a 49% increase year-over-year; highest quarter in history ●Q2 Test volume up 15% year over year to record levels ●Q2 Reimbursement improvement up 34% year-over-year...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results
May 12, 2023 16:05 ET | Interpace Biosciences, Inc.
 ●Q1 Revenue of $9.8 million; a 24% increase year-over-year; highest quarter in history ●Q1 Test volume up nearly 20% year over year to record levels ●Q1 41.9 million covered lives added, resulting...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results
March 27, 2023 16:05 ET | Interpace Biosciences, Inc.
 ●Q4 Revenue of $8.3 million  ●Cash and Cash Equivalents total $4.8 million as of December 31, 2022 PARSIPPANY, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern
November 14, 2022 16:41 ET | Interpace Biosciences, Inc.
Q3 Revenue of $8.2 million up 2% versus Prior YearQ3 Adjusted EBITDA PositiveCash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE)...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
August 15, 2022 16:05 ET | Interpace Biosciences, Inc.
 ●Q2 Revenue of $9.4 million down 16% versus Prior Year driven by an unexpected retroactive price decrease on ThyGeNEXT® ●2022 Year to Date Net Loss Improves by $1.5 million ●Days Sales Outstanding...